NASDAQ:CALA Calithera Biosciences (CALA) Stock Price, News & Analysis $0.0002 +0.00 (+100.00%) As of 01/17/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSustainabilityTrends About Calithera Biosciences Stock (NASDAQ:CALA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Calithera Biosciences alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.00▼$0.12Volume135 shsAverage Volume2,904 shsMarket Capitalization$974.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Read More… Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CALA Stock News HeadlinesCalithera Biosciences (NASDAQ:CALA) Now Covered by StockNews.comJanuary 20 at 2:43 AM | americanbankingnews.comCalithera Biosciences Inc (CALA)November 23, 2024 | investing.comElon Musk’s FINAL MoveI call it "Elon's Final Move" because his new AI venture will dominate Tesla...January 22, 2025 | Behind the Markets (Ad)Primecap Management Portfolio Exposed: Top Holdings RevealedApril 26, 2024 | msn.comArcus Biosciences Inc (RCUS)February 24, 2024 | uk.investing.comChristina CalaAugust 12, 2023 | npr.orgCalithera Biosciences cancels special meeting due to lack of quorumJune 29, 2023 | seekingalpha.comCALA - Calithera Biosciences, Inc.June 1, 2023 | finance.yahoo.comSee More Headlines CALA Stock Analysis - Frequently Asked Questions How have CALA shares performed this year? Calithera Biosciences' stock was trading at $0.0001 at the beginning of 2025. Since then, CALA shares have increased by 100.0% and is now trading at $0.0002. View the best growth stocks for 2025 here. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) released its earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share for the quarter, topping analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company earned $6.75 million during the quarter. When did Calithera Biosciences' stock split? Calithera Biosciences's stock reverse split on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX) and First Solar (FSLR). Company Calendar Last Earnings11/08/2021Today1/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALA CUSIPN/A CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees60Year Founded2010Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,870,000Free Float4,550,000Market Cap$974.00 OptionableNot Optionable Beta-0.89 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CALA) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.